Provider P88-23 New Commercial Reimbursement Policy: New Patient, Effective February 5, 2024 Read More
Provider P89-23 eviCore Healthcare Specialty Utilization Management (UM) Program: Medical Oncology Drug Prior Authorization Updates Read More
Provider P79-23 Prior Authorization Process for Minnesota Health Care Programs (MHCP), effective January 1, 2024 Read More
Provider QP81-23 Update: Medical Drug Update for Tofersen (Qalsody), Delandistrogene Moxeparvovec (Elevidys), and Donislecel (Lantidra) Read More
Provider QP82-23 Commercial Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Izervay™, and Veopoz™ Read More
Provider QP83-23 Commercial Pharmacy Benefit Exclusion for Budesonide-Formoterol Aerosol Inhaler and Tiotropium Bromide Inhalation Capsule Read More
Provider QP84-23 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective December 1, 2023 Read More
Provider QP85-23 MHCP Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Elrexfio™, Izervay™, Talvey™, and Veopoz™ Read More
